A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients

Summary

This trial assesses the safety of TEV-48125 when subcutaneously self-administered in Japanese migraine patients using an autoinjector (AI) at home. Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses. The first dose will be self-administered at the trial site under the supervision of the investigator and the second dose will be self-administered at home.

Timeline

Start

2020-06-17

Primary completion

2020-11-11

Completion

2020-11-11

Drugs

Indications